Accelerated Approval pathway for our ST-920 gene therapy product candidate for the treatment of Fabry disease.

Uncategorized

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results

Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 22, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2022 financial results.